Released Nov 7, 2013, after the close
10-Q filed Nov 7, 2013, 38 days after period end · 0001144204-13-059668
Q3 2013 · 10-Q
Revenue$2.28M$2.28M −38.7% vs Q3 2012+0.9% vs Q2 2013
Net Income-$5.75M-$5.75M N/M vs Q3 2012N/M vs Q2 2013
EPS Diluted-$0.06-$0.06 N/M vs Q3 2012N/M vs Q2 2013
Gross Profit$1,772,000−41.4%
Operating Income-$5,645,000N/M
Operating Cash Flowderived-$8,216,000N/M
Free Cash Flowderived-$8,543,000N/M
Margins · derived
Gross margin77.6%−3.6 pt vs Q3 2012
Operating margin-247.2%−97.9 pt vs Q3 2012
Net margin-251.6%−104.5 pt vs Q3 2012
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q3 2013 | Q3 2012 | Q3 2011 | Q3 2010 |
|---|---|---|---|---|
| Revenue | $2.28M | $3.72M | $1.13M | $3.18M |
| Net Income | -$5.75M | -$5.48M | -$8.88M | -$2.47M |
| EPS Diluted | -$0.06 | $0.06 | -$0.10 | $0.03 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR